ABSTRACT: Footwear-generated biomechanical manipulation of lower-limb joints was shown to beneficially impact gait and quality of life in knee osteoarthritis patients, but has not been tested in hip osteoarthritis patients. We examined a customized gait treatment program using a biomechanical device shown in previous investigations to be capable of manipulating hip biomechanics via foot center of pressure (COP) modulation. The objective of this study was to assess the treatment program for hip osteoarthritis patients, enrolled in a 1-year prospective investigation, by means of objective gait and spatiotemporal parameters, and subjective quality of life measures. Gait analysis and completion of questionnaires were performed at the start of the treatment (baseline), and after 3, 6, and 12 months. Outcome parameters were evaluated over time using linear mixed effects models, and association between improvement in quality of life measures and change in objective outcomes was tested using mixed effect linear regression models. Quality of life measures improved compared to baseline, accompanied by increased gait speed and cadence. Sagittal-plane hip joint kinetics, kinematics, and spatiotemporal parameters changed throughout the study compared to baseline, in a manner suggesting improvement of gait. The most substantial improvement occurred within 3 months after treatment initiation, after which improvement approximately plateaued, but was sustained at 12 months. Speed and cadence, as well as several sagittal-plane gait parameters, were significant predictors of improvement in quality of life. Clinical significance: Evidence suggests that a biomechanical gait therapy program improves subjective and objective outcomes measures and is a valid treatment option for hip osteoarthritis. ß
Hip osteoarthritis (OA) is a debilitating disorder characterized by loss of articular cartilage and joint space, formation of osteophytes, pain, stiffness, and deterioration of physical function, neuromuscular pattern, and gait. 1 It is particularly disabling since it affects ambulation. 2, 3 It is one of the major causes of disability in the elderly, 4 affecting an estimated 6.7-9.7 % of people over the age of 45 in the United States, 5, 6 with prevalence percentages increasing progressively with increasing age. [7] [8] [9] Hip OA is associated with antalgic gait which deviates significantly from healthy people. [10] [11] [12] [13] [14] [15] Patients may adopt abnormal gait patterns as compensatory mechanisms to avoid pain and joint loading, or due to joint laxity and joint deformity. The vast majority of hip OA gait analysis studies emphasize sagittal-plane gait parameters used as diagnostic indicators of hip OA, as well as indicators of efficacy of treatment interventions. Decreased hip flexion/extension range of motion (ROM), 10, 12, [16] [17] [18] peak extension angle, 10, 14, 15, 17, 19, 20 external extension moment, 12, 21 stride and step length, 14, 15, 17, 22 cadence, 15, 17 single support duration, 17 and gait speed, 10, 14, 15, 17, 22 increased peak hip flexion angle, 19 and overall gait asymmetry 12, 13, 17, 21 are consistent features of hip OA. Decreased extension moment is significantly correlated with increased level of pain, 12, 21 while loss of hip extension may be a pain avoidance mechanism to decrease joint load. 17 Efficacy studies using sagittalplane gait parameters as clinical outcome measures report change in gait speed, [23] [24] [25] [26] [27] stride length, 23, 25, 27 single-support duration, 26, 28 gait symmetry, 26 sagittalplane ROM, 23 peak extension angle, 27 peak flexion moment, 23 and peak extension moment 11, 23 post total hip replacement or pharmacological treatment.
The current nonsurgical and nonpharmacological treatment recommendations for hip OA include appropriate footwear; however, according to Osteoarthritis Research Society International (OARSI) recommendations for the management of hip and knee OA, this recommendation is based on expert opinion alone and there have been no controlled trials of footwear in patients with hip OA. 29 Recent advances in this field from our research group have suggested clinical potential for footwear-generated manipulation of hip biomechanics to benefit hip OA patients by improving gait parameters associated with the hip 30, 31 ; however, these studies investigated only immediate impact of a foot-worn device on gait. Therefore, the objective of the study was to assess the outcome of a 1-year long noninvasive footwear-based gait therapy program for hip OA patients. Based on a 12-week retrospective study, in which hip OA patients showed improvement in quality of life (QoL) measures and spatiotemporal parameters following the same gait treatment intervention as the present study, 32 we hypothesized that self-reported QoL measures would improve throughout the 1-year treatment program. We further hypothesized that the improvement would be accompanied by and attributed to significant biomechanical changes, as seen by significant changes in sagittal-plane gait and spatiotemporal parameters. We undertook a comprehensive search of sagittal-plane gait outcome measures found in the literature and used them as outcome measures for the efficacy of the treatment.
METHODS Participants
Twenty-six females with hip OA were recruited from the Department of Orthopedics at Rambam Medical Center, Haifa, Israel and Ha'Emek Medical Center, Afula, Israel, and assigned to the study by senior orthopedic surgeons. One patient was removed from the study due to severe knee pain that may have indicated a pre-existing condition. One patient left the study due to a serious health problem that was unrelated to hip OA. Three patients failed to attend all four testing sessions and thus were not included in the analysis. Twenty-one patients (11 bilateral hip OA, 10 unilateral hip OA) ( Table 1 ) attended all four testing sessions and successfully completed the study. All patients had symptomatic hip OA according to the American College of Rheumatology criteria for hip OA, with radiographic evidence of Kellgren-Lawrence (K-L) grades 2-4. 16, 33 All bilateral hip OA patients had a self-reported more symptomatic leg which they indicated upon initiation of their participation in the study. QoL measures were assessed by the 24-item 100 mm Visual Analog Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) 34 and the 36-item Short Form 36 Health Survey (SF-36) 35 questionnaires. Exclusion criteria were any orthopedic, musculoskeletal, or neurological pathology, previous surgery of the back and lower limbs, any other co-morbidities affecting the back and lower limbs, any problems maintaining balance, history of recurrent falls, any condition that increases susceptibility of falls, loss of balance, or injury, and use of a walking aid. X-rays were taken prior to the study to confirm the presence of hip OA. Approval of the Ethics Sub-Committee was obtained and informed consent was given by all participants. The study was registered in the NIH clinical trial registration system (NCT01450254). The purpose and methods of the study were explained to the subjects.
Foot-Worn Biomechanical Intervention
The APOS biomechanical device (APOS System, APOSMedical and Sports Technologies Ltd., Herzliya, Israel) was used. A detailed description of the device was previously reported. 36 In brief, customized calibration of the device is accomplished using a platform in the form of a shoe in which two adjustable convex-shaped biomechanical elements are attached to the feet by means of a shoe sole specially designed with two mounting rails (Fig. 1) . The convex elements can be moved in a continuous fashion in the transverse plane of the foot.
The device elements were custom-positioned for each patient by a single trained physiotherapist at the start of the 1-year gait therapy program, and repositioned as necessary during the course of the treatment program which, along with the device, is FDA and CE approved. In accordance with APOSTherapy treatment protocol, the physiotherapist positioned the device elements according to feedback from the patient about pain, as well as her own observational gait analysis, to optimally align lower-limb joints during gait. Patients were instructed to follow a treatment protocol in which they walk with the device every day for a cumulative period of time which increases gradually over 1 year from 10 min to 2 h or more. By custom-positioning the device elements, the locus and orientation of the ground reaction force (GRF) is repositioned, thus shifting the foot center of pressure (COP), 31, [36] [37] [38] 39 and hence kinematics and kinetics of the joints of the lower limbs are significantly altered. 30, 31, [36] [37] [38] The convexity of the device elements reduces stability and "forces" the user to adopt the new COP with the associated gait changes. The device works on the principle of motor learning, such that by training (walking) in the device for a set period of time daily, patients are retrained to walk with a more normal or beneficial gait. 40 Other than adhering to the treatment program, the treatment itself is a passive process and does not require conscious effort by the patient.
Experimental Protocol
The study is a prospective case series with Level of Evidence IV. The study is designed such that the baseline parameters collected at the initiation of treatment serve as the control measures, to which subsequent outcomes measures are compared, in order to test for improvement over time.
Data Acquisition and Processing
Patients underwent testing barefoot during four testing sessions throughout a 1-year period. The first testing session (TS1) was undertaken immediately before initiation of the treatment program. The next three testing sessions (TS2, TS3, and TS4) were performed 3, 6, and 12 months, respectively, after TS1.
Three-dimensional motion analysis was performed during each testing session using an 8-camera Vicon motion analysis system (Oxford Metrics Ltd., Oxford, UK) for kinematic data capture, at a sampling frequency of 100 Hz, using a 16 bit A/D board. The three constituent components of the ground reaction force, measured along the medio-lateral, anteropostierior, and vertical orthogonal axes were recorded by two 3-dimensional AMTI OR6-7-1000 force plates (Advanced Mechanical Technology, Inc., Watertown, MA) placed in tandem in the center of a 10-m walkway, at a sampling frequency of 1,000 Hz. Kinematic and kinetic data were synchronized and collected simultaneously while subjects (Fig. 2) . 41 The kinematic model inputs include subject anthropometric measurements of leg length, knee width, and ankle width. The lower-limb model models the lower body as a system of rigid segments, including the pelvis, thigh, shank, and foot segments. The methods presented in Kadaba et al. 41 and Davis et al. 42 are then used in the "PlugInGait" model to estimate joint and Euler angles. A knee alignment device (KAD; Motion Lab Systems Inc., Baton Rouge, LA) was used to estimate 3-dimensional alignment of the knee flexion axis during a static trial. Preliminary processing of the raw gait data, including smoothing of the data, was performed by a preset algorithm in "PlugInGait." Joint angles were calculated based on marker locations using "PlugInGait," and joint forces and moments were calculated via "PlugInGait" using inverse dynamic analyses from kinematic data and the 3-dimensional GRFs. Joint kinetics were normalized for body mass.
Various gait parameters were recorded during each of the four testing sessions. Peak hip flexion and extension angles and moments were calculated. The following spatiotemporal parameters were calculated: Gait speed, cadence, single support duration, double support duration, and stride length. Gait speed was calculated automatically using "PlugInGait" as stride length divided by stride time, where stride length is calculated as the distance from the ipsilateral toe marker's position at the first ipsilateral foot contact to the ipsilateral toe marker's position at the second ipsilateral foot contact, and stride time is calculated as the time between successive ipsilateral foot strikes. Self-reported QoL was measured using the SF-36 and WOMAC questionnaires at each testing session. The SF-36 is a 36-question multiple-choice form questionnaire, while the WOMAC is a 24-item questionnaire completed by making a vertical mark on a 100 mm horizontal analog scale in response to each question. Each questionnaire was scored by standard scoring instructions according to eight subgroupings of questions (subscales) for the SF-36 43 and three subgroupings for the WOMAC 44 pertaining to specific physical or emotional aspects of QoL. In the present study, we report only physical subscale scores (pain and physical function for SF-36, and pain, physical function, and stiffness for WOMAC) as the emotional aspect of QoL was not of particular interest in the present study. SF-36 subscale scores are calculated as the average of the scores for the items pertaining to each subscale and reported on a scale from 0% to 100%, with a greater score indicating a better QoL. WOMAC subscale scores are calculated as the sum of the scores for the items pertaining to each subscale and reported in mm (pain 0-500 mm, physical function 0-1700 mm, stiffness 0-200 mm), with a lesser score indicating a better QoL.
Statistical Analysis
Data were analyzed by a biostatistician (AH) using R ß version 3.2.3 (Vienna, Austria). Linear-Mixed Effects (LME) Models were used to test for changes in each QoL, spatiotemporal, and gait kinematic and kinetic parameter over time compared to baseline (difference from TS2, TS3, and TS4 compared to TS1). Fixed effects terms that were included in the models were: Subgroup (unilateral hip OA, bilateral hip OA) and leg (more symptomatic, less or asymptomatic).
Patient number (1-21) was included as a random effect term. Linear-Mixed Effects Regression Models were used to test if changes in objective spatiotemporal and gait parameters were significant predictors of improvement in physical QoL subscale scores. Each QoL subscale score was set as a dependent variable, while all objective spatiotemporal and gait parameters were included as fixed effects. Patient number was included as a random effect. Results for the LME Models were reported for the unilateral and bilateral hip OA subgroups separately when the interaction term for testing session (TS1-TS4) and subgroup was significant, as this indicates that the parameter of interest changed distinctly for one or both of the subgroups; otherwise, the results for the two subgroups were pooled together, indicating that the parameter of interest changed similarly over the group as a whole across testing sessions. The same was true for other terms, however no interaction terms were significant in those cases. Variance estimation in all the LME regression models were done using restricted estimate maximum likelihood (REML). All reported p values are two-sided. Significance level was set at 0.05 for all statistical tests.
RESULTS
Results for QoL (Table 2) , spatiotemporal (Table 3) , and kinematic and kinetic parameters (Table 4) are reported as the difference in each parameter between baseline (TS1) and each subsequent testing session (TS2-TS4). Actual results for each testing session are provided in Table S1 (QoL parameters), Table S2 (spatiotemporal parameters), and Table S3 (kinematic and kinetic parameters). significantly improved in all testing sessions compared to baseline for the two groups pooled together.
Quality of Life
The LME Model indicated significant interaction between testing session and group for WOMAC Physical Function, Stiffness, and Pain, and thus results are presented separately for each group. In general, all WOMAC subscale scores improved significantly compared to baseline for all testing sessions, except for WOMAC Stiffness and Pain in the bilateral group at TS3 only. The unilateral group showed greater improvement compared to baseline in nearly all testing sessions. WOMAC Physical Function improved by 48% (p ¼ 0.001), 68% (p ¼ 0.001), and 59% (p ¼ 0.001) at TS2, TS3, and TS4, respectively, compared to baseline for the unilateral group. It improved by 35% (p ¼ 0.001), 24% (p ¼ 0.023), and 31% (p ¼ 0.002) at TS2, TS3, and TS4, respectively, for the bilateral group. WOMAC Stiffness improved by 23% (p ¼ 0.015), 61% (p ¼ 0.001), and 44% (p ¼ 0.001) at TS2, TS3, and TS4, respectively, compared to baseline for the unilateral group. It improved by 33% (p ¼ 0.007) and 25% (p ¼ 0.045) at TS2 and TS4, respectively, for the bilateral group. WOMAC Pain improved by 57% (p ¼ 0.001), 72% (p ¼ 0.001), and 59% (p ¼ 0.001) at TS2, TS3, and TS4, respectively, compared to baseline for the unilateral group. It improved by 41% (p ¼ 0.004) and 43% (p ¼ 0.002) at TS2 and TS4, respectively, for the bilateral group. Table 3 shows results of spatiotemporal parameters and the statistical analysis. Cadence was significantly 
Spatiotemporal Parameters
Mean (standard error) of change in kinetic and kinematic gait parameters for each testing session (TS2, TS3, TS4) compared to baseline (TS1), where the LME model did not include speed as a predictor. Group is either unilateral or bilateral disease. In variables where the group variable was omitted "Both" represents the two groups pooled together. A positive value indicates an increase in the parameter compared to baseline, while a negative value indicates a decrease.
Ã Statistically significant result. increased in all testing sessions compared to baseline for the two groups pooled together. The LME Model indicated significant interaction between testing session and group for speed, and thus results are reported separately for each group. Speed increased significantly compared to baseline for all subsequent testing sessions in both unilateral and bilateral groups. The unilateral group showed greater increase in speed compared to baseline in all testing sessions. Single support duration did not change significantly over time and thus was not included in Table 3 , but is provided in the Supplementary Material. For double support duration, the LME Model indicated interaction between testing session and group and thus results are reported separately for each group. Double support duration decreased significantly for all testing sessions compared to baseline for the unilateral group, whereas it did not change significantly over time for the bilateral group. For stride length, there was an interaction between testing session and group and thus results are reported separately for each group. Stride length significantly increased in the unilateral group for all testing sessions compared baseline, while it did not change significantly over time for the bilateral group. Table 4 shows results of kinematic and kinetic gait parameters and the statistical analysis. Significant results are reported below as percentage changes to aid in interpretation. The LME Model indicated significant interaction between group and testing session for peak flexion angle, and thus results are reported separately for each group. Peak flexion angle did not change significantly over time for the unilateral group, whereas it was significantly decreased by 26% (p ¼ 0.001) compared to baseline only at TS2 for the bilateral group. Peak extension angle was increased significantly by 212% (p ¼ 0.001) only at TS2 compared to baseline for the two groups pooled together. For peak flexion moment, the LME model indicated significant interaction between group and testing session and thus results are reported separately for each group. Peak flexion moment was increased at TS2 and TS3 by 16% (p ¼ 0.011) and 22% (p ¼ 0.001), respectively, for the unilateral group, and at TS3 and TS4 by 20% (p ¼ 0.049) and 29% (p ¼ 0.005), respectively, for the bilateral group. Peak extension moment was increased significantly by 16% at both TS2 (p ¼ 0.005) and TS3 (p ¼ 0.008), while a possible statistical trend was observed at TS4 (increased by 11%; p ¼ 0.053), for the two groups pooled together. Table 5 shows results of the LME Regression Model analysis. Peak extension angle and moment of the less symptomatic leg, single support duration of the less symptomatic leg, and gait speed were predictors of WOMAC Physical Function, with all being statistically significant except for single support duration. Peak extension angle and moment of the less symptomatic leg, peak flexion moment of the less symptomatic leg, and gait speed were predictors of WOMAC Stiffness, with all being statistically significant except for peak flexion moment. Gait speed was the sole and significant predictor of SF-36 Physical Function. Peak extension and flexion moments for both legs, double support duration, stride length of the less symptomatic leg, and cadence were predictors of WOMAC Pain, with peak extension and flexion moments of the less symptomatic leg, stride length of the less symptomatic leg, and cadence being statistically significant. Peak flexion angle of the less symptomatic leg, peak flexion moment of the more symptomatic leg, stride length of the less symptomatic leg, and cadence were predictors of SF-36 Pain, with peak flexion moment of the more symptomatic leg and cadence being statistically significant.
Sagittal-Plane Gait Parameters
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DISCUSSION
In accordance with the hypothesis, self-reported QoL improved significantly during the 1-year study period in both bilateral and unilateral hip OA groups. All physical subscale scores for WOMAC and SF-36, with the exception of SF-36 Physical Function for the bilateral group, were improved at 3 months and remained improved at 12 months. Although, SF-36 Physical Function for the bilateral group did not change significantly over time, the WOMAC Physical Function score was significantly improved at all testing sessions compared to baseline. A previous study found that while WOMAC and SF-36 questionnaires are both adequate to measure changes in pain, WOMAC is superior to SF-36 in capturing changes in physical function. 45 Also in accordance with the hypothesis, significant changes in spatiotemporal parameters occurred concurrently with improvement in QoL, and were significant predictors of QoL. Gait speed and cadence were significantly increased from baseline at all subsequent testing sessions. Gait speed has been defined as a crucial outcome measure of hip function after medical intervention. 28 In agreement with this, SF-36 scores were shown to increase as walking speed increased post total hip arthroplasty. 46 Small meaningful change in gait speed has been defined as 0.05 m/s and substantial meaningful change as 0.1 m/s for older adults. 47, 48 According to these criteria, the unilateral group had substantial meaningful change in gait speed for all subsequent testing sessions after baseline, while the bilateral group had small meaningful change. Increase in gait speed was found to be a significant predictor of improvement in SF-36 and WOMAC Physical Function, and WOMAC Stiffness, while increase in cadence was a significant predictor of improvement in WOMAC and SF-36 Pain. The greater increase in gait speed in the unilateral group may explain why double support duration decreased and stride length increased significantly over time for the unilateral group only.
Lastly, and also in accordance with the hypothesis, significant changes in hip joint gait kinematics and kinetics occurred concurrently with improvement in QoL and were significant predictors of QoL measures. The most notable result was the increase in extension moment over the study period. Although, this was significant at 3 and 6 months only, there was a possible statistical trend at 12 months. Previous studies have shown that extension moment is significantly correlated to level of pain, with increased extension moment being associated with decreased pain. 12, 21 In the present analysis, peak extension moment of the less symptomatic limb was a significant predictor of WOMAC Physical Function, Stiffness, and Pain. Peak flexion moment was significantly increased for the unilateral group, but did not remain significant at 12 months. For the bilateral group, peak flexion moment increased with time, as did the level of significance, reaching significance by 6 months, and even greater significance at 12 months. Peak flexion moment of the less symptomatic leg was a significant predictor of WOMAC Stiffness and Pain, while peak flexion moment of the more symptomatic limb was a significant predictor of SF-36 Pain. With respect to peak flexion angle of the bilateral group, and peak extension angle of the pooled groups, there appears to be a transient response at 3 months, at which peak flexion angle is reduced and peak extension angle in increased significantly. After 3 months, these changes are no longer significant. Peak extension angle of the less symptomatic limb was a significant predictor of WOMAC Physical Function and Stiffness. Peak flexion angle was not a significant predictor for any QoL parameter, however a possible statistical trend (p ¼ 0.057) was indicated for the less symptomatic limb for SF-36 Pain. A previous study found increased flexion angle and decreased extension angle in hip OA patients compared to controls. 19 This phenomenon was significantly correlated with cartilage lesions. Thus a reduction in flexion and increase in extension may indicate an improvement in physical status. The flexion angle and extension angle were still reduced and increased, respectively, at 6 and 12 months, although the difference may not have been large enough to be significant at these time points. All objective gait parameters, with the exception of single and double support duration and flexion angle, were significant predictors of at least one QoL physical subscale measure. Although this was the case, in most instances this was true for gait parameters of the less symptomatic leg only. Although, gait parameters were similarly affected by the treatment over time, as evidenced by the insignificance of the interaction terms between gait parameters and testing sessions, the more painful limb may have been more largely affected by the change in speed, thus masking the effect of the treatment. Thus, it may be that the treatment had a more pronounced effect on the less symptomatic leg with regards to QoL. This is in agreement with the more pronounced results seen in the unilateral group with a lesser K-L score than that of the bilateral group.
There are several noteworthy results in the study. It is apparent that patients improve most within 3 months after initiation of treatment, after which they approximately plateau. The improvement is sustained throughout the year, but does not change substantially from one testing session to the next relative to the initial change seen at the 3-month testing session. This can be seen by QoL scores and objective gait parameters. These results may indicate a transient response to the treatment, followed by a steady-state or declining response. The exception to this was the peak flexion moment for the bilateral group which continued to increase over time. This could be due to a combination of increased speed and improvement from the treatment. It must also be noted that the unilateral group had greater improvement than the bilateral group, however we cannot conclude from this result that the treatment is more effective in unilateral hip OA patients, as the bilateral group had a greater K-L score.
It must be acknowledged that speed and cadence increased significantly compared to baseline. The impact of increasing speed and cadence on spatiotemporal, kinetic, and kinematic parameters of gait is well-known. Increasing gait speed tends to increase peak flexion and extension angles, 49 increase hip ROM, 49 increase joint moments, [50] [51] [52] increase stride length, 51, 53 decrease double support duration, 51 increase single support duration, 49 and accentuate pathological gait features. 49 We did not control for speed across testing sessions, such that we could observe true changes in gait, due to the treatment, to emphasize clinical meaning of results. Additionally, previous research has shown that gait parameters are detrimentally affected when subjects walk at a speed which is not self-selected. Self-selected speed, as used in this study, has been shown to significantly reduce variability of gait from stride to stride in hip OA patients, with the highest variability of gait shown at speeds which differed from self-selected. 54 Several studies have supported including data analysis in OA patients that is unadjusted for speed. 10, 55 We thus elected to analyze the study outcomes unadjusted for speed and include Linear-Mixed Effects Regression Models with speed also included as a potential predictor of QoL. In the case, that kinematic or kinetic parameters were found to be significant predictors of QoL scores, we may assume that this is true despite the change in speed. Indeed, almost all changes in objective gait parameters were significant predictors of one or more QoL parameters when the effect of speed was considered.
It should be mentioned that we stated that the treatment protocol and device work on the principle of motor learning. Previous studies from our group have indeed shown significant optimization of the gait pattern in knee OA patients following a similar treatment protocol with the same device as the present study, when patients underwent barefoot gait analysis. 40, 56 Although, there have not to date been any studies which directly prove that the device induces motor learning, previous studies from our group, as well as the present study, provide evidence that suggests that this is the case. In the previous study in a knee OA cohort, 40 as well as in the present study, the significantly more optimal gait pattern is observed within the first 3 months of treatment when patients walk without the device (barefoot), and remained improved throughout the duration of the studies, suggesting motor learning.
We must note that we have emphasized a shift in COP as the mechanism of the device, although we did not measure COP in the present study. In previous studies by our group using the study device, COP was measured by two methods: (i) using pedobarography, in which COP is measured using an in-shoe measurement device equipped with an array of pressure sensors, 38, 39 and (ii) by calculating the perpendicular distance from the resultant GRF vector (measured by the force plates) to the antero-posterior 37 or mediolateral 31, 36 foot axis defined by the reflective markers on the foot. In these studies, it was reported that when the biomechanical elements of the device are shifted in the transverse plane of the foot, along either the antero-posterior or medio-lateral foot axis, the COP shifted accordingly. This was shown in both healthy subjects 36, 37, 39 and knee OA patients, 38 as well as in a cohort of bilateral hip OA patients. 31 In the current longitudinal study, the COP was not measured for several reasons. At the time of testing session 1, after data was collected for the present study, we conducted a parallel study in which we assessed the effects of seven different COP locations on the biomechanics of the hip joint during gait. 31 This study resulted in lengthy experiments with patients having to walk many times back and forth in the laboratory, in many instances for a duration of time beyond their comfort level. Measurement Method i would have required additional walking trials and preparation time that likely would have caused undue stress or pain to several of the patients. Method ii, which allows COP to be calculated using the reflective markers and does not require additional experimentation or preparation time, is a reliable method when markers are not moved in between testing sessions. However, in a longitudinal study such as the present one, where markers are repositioned after several months, even a small error in placement of the markers, or variability in the exact positioning of the markers, would have an effect on the COP calculation that may be greater than the COP shift itself. Finally, since the device elements are custom-positioned for each specific patient, and repositioned during the course of the study, we would not necessarily expect to see a pattern in COP shift that is common to the cohort as a whole, but rather a general change in the COP from the baseline COP location for each patient. Thus, due to the limitations of these methods unique to the present study, we elected not to measure COP and to rely on the various previous studies which have confirmed that COP is shifted when the device elements are shifted.
In the present study, we used the "PlugInGait" kinematic model, otherwise known as the Conventional Gait Model. 41, 57, 58 The marker set used along with the model is very widely used and has been validated and tested for repeatability in several studies. 57, 59 These studies found superior repeatability specifically for sagittal-plane gait parameters, as measured in this study. Further, excellent between-day repeatability for hip, knee, and ankle sagittal-plane kinematics was reported, as well as good repeatability of between-day kinetics. 59 Thus a reliability/validity test was not performed in the study. Additionally, gait of hip OA patients is inherently variable, and thus this was not feasible. Regardless, great care was taken to precisely position the markers on the anatomical landmarks, and the markers were placed by the same investigator for all testing sessions. Additionally, since we observed a distinct pattern of changes in sagittalplane gait parameters which were statistically significant for the cohort as a whole, or each subgroup as a whole, we believe that our results are valid.
Finally, we must emphasize that the treatment provided in this study was based on clinical observational gait analysis to optimally align lower limb joints, and patient feedback about pain and comfort. Adjustments were made during the course of the year to the treatment device, based on the same factors, as part of the AposTherapy customized treatment protocol. The researchers did not know the particular shifts in the biomechanical device elements made for each patient and thus cannot attribute biomechanical changes in the hip joint to specific biomechanical element locations in the present study. In our previous work on both healthy subjects 30 and bilateral hip OA patients, 31 we found a specific location of the biomechanical elements that led to a significantly reduced hip joint force. We described in detail a possible biomechanical mechanism which initiated with shift in foot COP and commenced with the reduction in joint force. In the present study, however, the COP shift was different for each patient, and the COP may have been shifted to any location in the transverse plane of the foot. Despite this, we observed a distinct pattern of change in sagittal-plane and spatiotemporal gait parameters that is common to the cohort as a whole, or to the unilateral or bilateral hip OA group as a whole. Thus, we speculate that the custom-shift in COP was not the direct cause of changes in gait parameters observed in the study, but rather altered the hip biomechanics in such a way that caused a reduction in pain, which subsequently caused an alteration in the clinically relevant sagittal-plane and spatiotemporal gait outcome parameters of the study. With respect to the specific changes in gait parameters, we cannot express an exact cause and effect relationship between any of the kinematic, kinetic, and spatiotemporal parameters. A change in any one parameter imminently causes a change in many of the other parameters, because of their complex interdependence. As such, changes in gait parameters occur simultaneously making it impossible to decipher an explicit chain of events. Thus, it is beyond the scope of this study to describe the biomechanical mechanism by which gait parameters were altered. Regardless, in the present study, we found evidence for the efficacy of the treatment investigated based on significant increase in subjective reporting of QoL, significant increase in gait speed and cadence which were significant predictors of QoL measures, and several significant changes in hip kinetics and kinematics which were also significant predictors of QoL measures. Although we found evidence for the efficacy of the treatment, future investigation should be based on our previous studies, and should investigate longitudinal effects of the specific COP location that reduced hip joint force. We speculate that this may further improve the outcome measures of the study. Also, additional experimental examination is required to further quantify the benefits and weaknesses of the treatment. The present study, however, sets an important baseline for the existing treatment protocol to compare with in future study, and also suggests that the intervention is a valid option for treatment of hip OA.
Several limitations of the study must be mentioned. The results apply only to female patients with pathological and anthropometrical characteristics similar to the study cohort. In addition, the study did not include a control group. Initially, the study was to include a control group, however we were presented with difficulty in recruiting enough patients in a reasonable time span with hip OA who were willing to try nonsurgical treatment for 1 year and had no other comorbidities affecting the lower limbs or spine. Regardless of this limitation, the pathophysiology of hip OA is wellknown. OA is a progressive disease with progression of physical abnormalities over time 60 that do not spontaneously improve. Thus, the outcomes of the present study represent improvement relative to the patient group's baseline and not relative to healthy controls, but which can be attributed to the treatment and not spontaneous improvement.
